In today's episode of "This Week in Psychedelic Stocks", we have News on MindMed (MMED / MMEDF/MMQ), Compass Pathways (CMPS), Cybin (CYBN) & Mydecine (MYCO / MYCOF). I covered some breaking news on MindMed yesterday in our impromptu episode on the MindMed stock being added to the FTSE so that MMED / MMEDF news is not in this episode. However, this wasn't the only big news this week. Compass Pathways (CMPS) received not one but 2 new patents and surely, some of you might find this news worth discussing... We will cover the latest developments in the field writ large. This means we will cover any stories that affect the all the companies in this field, as well as company specific developments. Timestamps: 0:00 - Intro 0:55 - Psilocybin to treat OCD? 5:28 - The Psychedelic Industry worth $300 Billion by 2027? 8:24 - MindMed stock news ( MMED / MMEDF / MMQ) 11:39 - Compass Pathways stock news ( CMPS) 15:07 - Entheon Biomedical Corp stock news ( ENBI / ENTBF ) 19:25 - Cybin stock news ( CYBN / CLXPF ) 22:52 - Mydecine stock new ( MYCO / MYCOF ) So that's it for This Week in Psychedelic Stocks fellow psychedelic investors! I hope you guys found some value in this and I'll keep you posted for more changes! Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news! Follow us on social media! 🙌 Instagram: @psychedelicinvestor email: thepsychedelicinvestor@gmail.com Facebook: @thepsychedelicinvestor Music: www.bensound.com https://benzinga.grsm.io/jameshallifax1834 https://benzinga.grsm.io/thepsychedelicinvestor DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments. #MindMed​​ ​#CompassPathways​​ #Entheon

Will Ark Invest (ARKK) and Cathie Wood invest in MindMed ( MMED / MMEDF/ MMQ) or other Psychedelic Stocks? In this episode, Cathie Wood talks to Kevin O'Leary about the potential for psychedelic stocks and MindMed. Kevin O'Leary is a BIG bull in MindMed, but what does Cathie Wood think? Will Ark invest in MindMed? Well, no. She is clear that Ark does not invest in binary outcomes, which MMED / MMEDF cleary is. Having said this, the door may be left open for the future, as ARKK invests in Healthcare companies using artifical intellegence, exactly what MindMed's Albert division is working on. Also, once clinical trial results come in, MindMed will no longer be a binary choice. SO anything is possible. I hope this little impromptu episode added some life and joy to your live and that you guys found some value in this. Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news! Follow us on social media! 🙌 Instagram: @psychedelicinvestor Email: thepsychedelicinvestor@gmail.com Facebook: @thepsychedelicinvestor Music: www.bensound.com https://benzinga.grsm.io/jameshallifax1834 https://benzinga.grsm.io/thepsychedelicinvestor DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments. #MindMed​​​ ​#MindmedNews​​​ #PsychedelicStocks

The University of Wisconsin is the first in the U.S. to offer a master's degree in development of psychedelic medicine.